Cumberland Pharmaceuticals

Cumberland and Caldolor® were featured in the August edition of McMahon Publishing’s Pain Medicine News “Corporate Profiles.” You can see the feature here: https://lnkd.in/e4dj2J2Q.   For full prescribing information, including the boxed warning, visit https://lnkd.in/eBX2nqdc.

We were honored to speak to the Greater Los Angeles Area Oncology Nursing Society and the SAN GABRIEL VALLEY SOCIETY OF HEALTH-SYSTEM PHARMACISTS about Sancuso. Thank you for having us and a big thank you to all who attended the event!

If you missed our second quarter earnings call last week, we’ve outlined a few updates we discussed, including:  A strong financial performance during the quarter, with just under $10 million in net revenues, representing 16% in sequential growth from the first quarter of the year.     A recent study published in Antimicrobial Agents and Chemotherapy found that Vibativ – our potent antibiotic – could be an effective treatment for anthrax inhalation.     Kristalose, our prescription-strength laxative, is now covered on Wisconsin Medicaid plans, in addition to New York and Texas.     After previously transferring the manufacture of Sancuso – our oncology support medication – we introduced our newly Cumberland-packaged product made at the new facility.  Read the full overview here: https://lnkd.in/gjHH6xDR

During this afternoon’s earnings call, we were pleased to share that Cumberland delivered a strong financial performance for the second quarter of 2024, with 16% sequential revenue growth. Overall, the quarter was successful, with several positive developments at Cumberland. We remain very optimistic about our future prospects and believe we are on track to achieve significant revenue growth and positive cash flow from operations this year.    Learn about our recent developments and see our full financial report by visiting https://lnkd.in/eXh95-Kd.    Or, to listen to a replay of the call, visit https://lnkd.in/e5GbVjnQ.

If you missed our earnings call last week, we’ve outlined some of the updates we discussed, including: – A Special Report published in industry publications presenting the growing amount of data supporting the use of our Caldolor (ibuprofen) injection as a standard of care for the treatment of pain and fever in adults, children and infants as young as 3 months of age. – The development of a special supply of compounded Vaprisol in support of critically ill patients. – The progression of our newest clinical program, which is evaluating ifetroban in patients with idiopathic pulmonary fibrosis, the most common form of progressive fibrosing interstitial lung disease. Read the full overview here: https://lnkd.in/egTeNDte.  

We were pleased to report our first quarter 2024 financial results and share several positive developments during this afternoon’s earnings call. Overall, it’s been a productive start to the year, and we remain very optimistic about our company’s fundamentals and future. Learn about our recent developments and see our full financial report by visiting https://lnkd.in/e6RzTMXm. Or, to listen to a replay of the call, visit https://lnkd.in/e-exJmrM. 

A huge congratulations to our CEO A.J. Kazimi, who was named to the Nashville Post's esteemed In Charge list. This annual list highlights Nashville's most influential leaders who are making an impact on the city and in their industries.    Join us in congratulating all of this year’s honorees who are pushing the city toward a brighter future.    https://lnkd.in/geM6HiRZ    #NashvillePostInCharge #Leadership #HealthCareLeadership   

A newly published report supports the use of our Caldolor® product as a standard of care across patient populations. As part of a comprehensive safety and efficacy developmental plan, Caldolor (intravenous ibuprofen, or IVIB) was studied in various treatment areas, including surgical pain, fever and nonsurgical acute pain. The results show it’s a safe and effective treatment for pain and fever in adults, children and infants as young as 3 months of age.    For takeaways from and a link to the full report, visit https://lnkd.in/esgpcx6z.  

Recently we shared several significant achievements Cumberland made during 2023. If you missed our earnings call, we’ve outlined some highlights for you, including: – Securing FDA approval on expanded labeling for our Cadolor product to be administered for the treatment of pain and fever in patients 3 to 6 months of age – Sharing the positive results of the first pediatric study investigating the safety and pharmacokinetics of our Vibativ product – Expanding our oncology sales division as we work to deliver our newest brand, Sancuso, to cancer patients Read the full overview here: https://lnkd.in/eWYWvikH.

We were pleased to report our 2023 financial results during this afternoon’s earnings call. In many ways, 2023 was a productive and important year for Cumberland, as we were able to take key steps in laying the foundation for future success. We continued to integrate our newest products while delivering several significant achievements, which we recapped during the call. For more information, including full 2023 financials and an overview of company developments from the year, visit https://lnkd.in/eCG9JTxd. To listen to a replay of the call, visit https://lnkd.in/ei-k_n6b.